Dr. Henrique Bittencourt, MD PhD
Claim this profileCHU Sainte-Justine
Studies Acute Lymphoblastic Leukemia
Studies Neuroblastoma
2 reported clinical trials
12 drugs studied
Area of expertise
1Acute Lymphoblastic Leukemia
2Neuroblastoma
EWSR1-FLI1 translocation positive
EWS rearrangement positive
Clinical Trials Henrique Bittencourt, MD PhD is currently running
Onivyde + Talazoparib/Temozolomide
for Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm. In Arm A, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair, the cancer cells may die. In Arm B, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and temozolomide. Both of these medications work by damaging the DNA of the cancer call which may cause the tumor(s) to die. Once the highest doses are reached in Arm A and Arm B, then "expansion Arms" will open. An expansion arm treats more children and AYAs with recurrent or refractory solid tumors at the highest doses achieved in the phase I study. The goal of the expansion arms is to see if the tumors go away in children and AYAs with recurrent or refractory solid tumors. There will be 3 "expansion Arms". In Arm A1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and talazoparib. In Arm A2, children and AYAs with recurrent or refractory solid tumors, whose tumors have a problem with repairing DNA (identified by their doctor), will receive Onivyde and talazoparib. In Arm B1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and temozolomide. Once the highest doses of medications used in Arm A and Arm B are determined, then a phase II study will open for children or young adults with Ewing sarcoma that has recurred or is refractory following treatment received after the initial diagnosis. The trial will test the same 2 combinations of therapy in Arm A and Arm B. In the phase II, a participant with Ewing sarcoma will be randomly assigned to receive the treatment given on either Arm A or Arm B.
Recruiting1 award Phase 1 & 214 criteria
Stem Cell Transplant
for Acute Lymphoblastic Leukemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Recruiting3 awards Phase 2 & 3
More about Henrique Bittencourt, MD PhD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Henrique Bittencourt, MD PhD has experience with
- ATG Thymoglobulin
- Busulfan
- Cyclophosphamide
- Fludarabine
- Grafalon
- TBI
Breakdown of trials Henrique Bittencourt, MD PhD has run
Acute Lymphoblastic Leukemia
Neuroblastoma
Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Henrique Bittencourt, MD PhD specialize in?
Henrique Bittencourt, MD PhD focuses on Acute Lymphoblastic Leukemia and Neuroblastoma. In particular, much of their work with Acute Lymphoblastic Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Henrique Bittencourt, MD PhD currently recruiting for clinical trials?
Yes, Henrique Bittencourt, MD PhD is currently recruiting for 2 clinical trials in the USA. If you're interested in participating, you should apply.
Are there any treatments that Henrique Bittencourt, MD PhD has studied deeply?
Yes, Henrique Bittencourt, MD PhD has studied treatments such as ATG Thymoglobulin, Busulfan, Cyclophosphamide.
What is the best way to schedule an appointment with Henrique Bittencourt, MD PhD?
Apply for one of the trials that Henrique Bittencourt, MD PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.